MeSH tree: D12.776.377.715.548.114
New research from UCLA Health reveals that women continue to face barriers in accessing lung transplants compared to men, despite recent national policy changes aimed at making organ distribution more equitable.
Oct 22, 2025
0
10
For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...
Oct 21, 2025
0
13
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat ...
Oct 20, 2025
0
11
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...
Oct 20, 2025
0
14
Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant bacterial pathogens. The ...
Oct 15, 2025
0
16
Using millions of microscope images magnified up to 130,000 times, researchers from Radboud University Medical Center and Toronto have unraveled the structure of two key proteins in the malaria parasite. With this knowledge, ...
Oct 9, 2025
0
17
Australian researchers have discovered that an anti-inflammatory drug already being used to treat rheumatoid arthritis could dramatically improve recovery from heart attacks. The work is published in the journal Cardiovascular ...
Oct 8, 2025
0
52
We all know that asthma impacts breathing. What may be less known is that the disease, which restricts our airways due to inflammatory responses, can be caused throughout our lifetime by a variety of things. It can be treated ...
Oct 7, 2025
0
16
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating multiple sclerosis.
Sep 25, 2025
0
23
New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses ...
Sep 23, 2025
0
16
